BEVESPI AEROSPHERE
LAMALABA MDI
Glycopyrrolate / Formoterol fumarate · AstraZeneca
Active Medication & Mechanism
- Glycopyrrolate LAMA9 mcg per actuation
Long-acting muscarinic antagonist. Blocks M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction.
- Formoterol fumarate LABA4.8 mcg per actuation
Long-acting beta2-adrenergic agonist with rapid onset of action. Stimulates beta2-receptors, increasing cAMP and relaxing airway smooth muscle.
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
9/4.8 mcg
2 inhalations twice daily (morning and evening) → 36/19.2 mcg
FDA Approved
Long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Not Approved
Bevespi Aerosphere is NOT indicated for asthma. LABA without ICS in asthma increases risk of serious events.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
9/4.8 mcg 2 inhalations twice daily (morning and evening) → 36/19.2 mcg
COPD FDA Approved
Long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Asthma Not Approved
Bevespi Aerosphere is NOT indicated for asthma. LABA without ICS in asthma increases risk of serious events.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not indicated for relief of acute bronchospasm. Use a SABA.